biotech · Breast Cancer · Advanced Breast Cancer · PBYI
PUMA BIOTECHNOLOGY
PUMA BIOTECHNOLOGY, INC.
PUMA BIOTECHNOLOGY clinical programs — 11 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 10880 Wilshire Blvd, Los Angeles, CA 90024, US
- Founded
- 2010
- Employees
- 257
- Programs
- 40
- Drugs
- 23
- Patents
- 1
PUMA BIOTECHNOLOGY projects
11 ClinicalTrials.gov programs sponsored by PUMA BIOTECHNOLOGY.
PUMA BIOTECHNOLOGY has 11 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Digoxin
PUMA BIOTECHNOLOGY, INC.
Healthy
1 trial -
Lansoprazole
PUMA BIOTECHNOLOGY, INC.
Healthy
1 trial -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Healthy Subjects
3 trials -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Advanced Malignant Solid Tumors
3 trials -
Neratinib
PUMA BIOTECHNOLOGY, INC.
Neoplasms
1 trial -
Neratinib (HKI-272)
PUMA BIOTECHNOLOGY, INC.
Hepatic Insufficiency
1 trial -
Neratinib 160 mg
PUMA BIOTECHNOLOGY, INC.
Advanced Solid Tumor
1 trial -
Neratinib Pill
PUMA BIOTECHNOLOGY, INC.
Gastric Cancer
1 trial -
Osimertinib
PUMA BIOTECHNOLOGY, INC.
Lung Cancer Metastatic
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
Tumors
1 trial -
neratinib
PUMA BIOTECHNOLOGY, INC.
Healthy
5 trials
Frequently asked questions
How many clinical projects does PUMA BIOTECHNOLOGY have?
11 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.